Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 27:12:1384410.
doi: 10.3389/fpubh.2024.1384410. eCollection 2024.

Exploring the path to polio eradication: insights from consecutive seroprevalence surveys among Pakistani children

Imtiaz Hussain #  1 , Muhammad Umer #  1 , Ahmad Khan #  1 , Muhammad Sajid  1 , Imran Ahmed  1 , Kehkashan Begum  2 , Junaid Iqbal  2 , Muhammad M Alam  3 , Rana M Safdar  4 , Shahzad Baig  4 , Arie Voorman  5 , Jeffrey Partridge  5 , Sajid Soofi  1   2
Affiliations

Exploring the path to polio eradication: insights from consecutive seroprevalence surveys among Pakistani children

Imtiaz Hussain et al. Front Public Health. .

Abstract

Introduction: After trivalent oral poliovirus vaccine (tOPV) cessation, Pakistan has maintained immunity to type 2 poliovirus by administering inactivated polio vaccine (IPV) in routine immunization, alongside monovalent OPV type 2 (mOPV2) and IPV in supplementary immunization activities (SIAs). This study assesses the change in poliovirus type 2 immunity after tOPV withdrawal and due to SIAs with mOPV2 and IPV among children aged 6-11 months.

Methods: Three cross-sectional sequential serological surveys were conducted in 12 polio high-risk areas of Pakistan. 25 clusters from each geographical stratum were selected utilizing probability proportional to size.

Results: Seroprevalence of type 2 poliovirus was 49%, with significant variation observed among surveyed areas; <30% in Pishin, >80% in Killa Abdullah, Mardan & Swabi, and Rawalpindi. SIAs with IPV improved immunity from 38 to 57% in Karachi and 60 to 88% in Khyber. SIAs with IPV following mOPV2 improved immunity from 62 to 65% in Killa Abdullah, and combined mOPV2 and IPV SIAs in Pishin improved immunity from 28 to 89%. Results also reflected that immunity rates for serotypes 1 and 3 were consistently above 90% during all three phases and across all geographical areas.

Conclusion: The study findings highlight the importance of implementing effective vaccination strategies to prevent the re-emergence of poliovirus. Moreover, the results provide crucial information for policymakers working toward achieving global polio eradication.

Keywords: Pakistan; eradication; poliovirus; seroprevalence; type 2 immunity.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Study profile.
Figure 2
Figure 2
Seroprevalence by survey areas of Pakistan, 2016–2019. The points denote seroprevalence estimates, and lines indicate 95% confidence intervals. The x-axis represents the median month of the blood draw for children in the survey round.
Figure 3
Figure 3
Seroprevalence by birth cohorts. The points denote seroprevalence estimates, and lines indicate 95% confidence intervals. The x-axis represents birth in year-month format.
Figure 4
Figure 4
Seroprevalence of type 2 OPV in routine immunization, by study area. Bar heights represent seroprevalence, and lines show 95% confidence intervals.
Figure 5
Figure 5
Seroprevalence of type 2 OPV in areas targeted for mOPV2 campaigns. Bar heights represent seroprevalence, and lines show 95% confidence intervals.
Figure 6
Figure 6
Type 2 immunity by eligibility for SIA contain IPV. The bar heights represent seroprevalence, and lines show 95% confidence intervals.
See this image and copyright information in PMC

References

    1. Moffett DB, Llewellyn A, Singh H, Saxentoff E, Partridge J, Boualam L, et al. Progress toward poliovirus containment implementation – worldwide, 2019–2020. MMWR Morb Mortal Wkly Rep. (2020) 69:1330–3. doi: 10.15585/mmwr.mm6937a7, PMID: - DOI - PMC - PubMed
    1. Chard AN, Datta D, Tallis G, Burns CC, Wassilak SGF, Vertefeuille JF, et al. Progress toward polio eradication — worldwide, January 2018–march 2020. MMWR. (2020) 69:784–9. doi: 10.15585/mmwr.mm6925a4, PMID: - DOI - PMC - PubMed
    1. Haqqi A, Zahoor S, Aftab MN, Tipu I, Rehman Y, Ahmed H, et al. COVID-19 in Pakistan: impact on global polio eradication initiative. J Med Virol. (2020) 93:141–3. doi: 10.1002/jmv.26240, PMID: - DOI - PMC - PubMed
    1. Pakistan Polio Eradication Programme . (2023). Polio cases in provinces. Available at: https://www.endpolio.com.pk/polioin-pakistan/polio-cases-in-provinces
    1. Din M, Ali H, Khan M, Waris A, Ullah S, Kashif M, et al. Impact of COVID-19 on polio vaccination in Pakistan: a concise overview. Rev Med Virol. (2021) 31:e2190. doi: 10.1002/rmv.2190, PMID: - DOI - PubMed

Publication types

Substances